Core Points - Marvel Biosciences Corp. is accelerating the expiry date of warrants related to its non-brokered private placement unit offering, with the new expiry date set for November 5, 2025 [1][2] - As of October 3, 2025, 4,300,000 out of 5,000,000 warrants have been exercised, leaving 700,000 outstanding [2][3] - The company is developing MB-204, a novel drug aimed at treating neurological diseases, including autism, depression, and Alzheimer's Disease [3] Summary by Sections Company Announcement - Marvel Biosciences Corp. and its subsidiary Marvel Biotechnology Inc. are notifying about the acceleration of the expiry date of warrants from their private placement offering [1] - The offering consisted of 5,000,000 units priced at $0.10 each, with each unit including one common share and one warrant [1] Warrant Details - Each warrant allows the purchase of one common share at an exercise price of $0.15, expiring on July 19, 2026, unless the volume-weighted average trading price reaches $0.175 for five consecutive trading days [2] - The Triggering Event has occurred, leading to the new expiry date of November 5, 2025, for the remaining warrants [2] Company Vision and Product Development - The CEO, Rod Matheson, emphasized shareholder confidence with the exercise of 4,300,000 warrants, indicating strong belief in the company's vision and scientific foundation [3] - Marvel is focused on developing MB-204, a derivative of Istradefylline, to potentially treat various neurological disorders, expanding its therapeutic applications [3]

Core Points - Marvel Biosciences Corp. has successfully closed the second tranche of its non-brokered private placement, raising gross proceeds of $18,750 from the issuance of 150,000 units at a price of $0.125 per unit [1][2] - The proceeds from the offering will be allocated towards drug formulation, toxicology studies, and general working capital [5] - The company has clarified that no finders' fees or warrants were paid to Abinvest Corporation and Abingdon Capital Corp. as previously reported [3] Offering Details - The second tranche of the offering involved the issuance of 150,000 units, each consisting of one common share and one warrant [2] - Finders' fees of $1,312.50 were paid in cash, along with the issuance of 10,500 finder's warrants, which are exercisable at $0.175 per share for two years [2] - The offering is limited to accredited investors and is subject to approval by the TSX Venture Exchange [4] Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [7] - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which may also have applications in treating other neurological diseases [7][9] - The company is exploring the potential of MB-204 in addressing neurodevelopmental disorders such as autism, depression, Alzheimer's Disease, Rett Syndrome, and Fragile X Syndrome [9]